星空体育官方入口网站网址大全-登录入口官网

#非转移性前列腺癌#

10篇内容 | 818人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2216156, encodeId=553322161566c, content=<a href='/topic/show?id=5ad23250258' target=_blank style='color:#2F92EE;'>#前列腺切除术#</a> <a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a> <a href='/topic/show?id=ac971169310f' target=_blank style='color:#2F92EE;'>#癌症特异性生存率#</a>, objectTitle=Eur Urol Oncol：根治性前列腺切除术对根据STAMPEDE标准选择的高风险非转移性前列腺癌男性生存率的影响, objectType=article, longId=835509, objectId=5538835509d9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240718/1721289919736_92910.png, objectUrl=/article/show_article.do?id=5538835509d9, replyNumber=0, likeNumber=18, createdTime=2024-07-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5538835509d9, moduleTitle=Eur Urol Oncol：根治性前列腺切除术对根据STAMPEDE标准选择的高风险非转移性前列腺癌男性生存率的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5538835509d9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1589479, encodeId=93c115894e94f, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, objectTitle=Eur Urol：非转移性前列腺癌患者中，高强度聚焦超声局部治疗后的癌症控制结果 , objectType=article, longId=299087, objectId=d12e29908ecd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d12e29908ecd, replyNumber=0, likeNumber=66, createdTime=2022-02-19, rootId=0, userName=jinweidong, userId=022b17724229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d12e29908ecd, moduleTitle=Eur Urol：非转移性前列腺癌患者中，高强度聚焦超声局部治疗后的癌症控制结果 , moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d12e29908ecd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589478, encodeId=a43515894e88e, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, objectTitle=Eur Urol Focus：非转移性前列腺癌根治术后尿失禁的患者和肿瘤相关预后因素分析 , objectType=article, longId=211755, objectId=1f0d211e555f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f0d211e555f, replyNumber=0, likeNumber=61, createdTime=2021-05-26, rootId=0, userName=jinweidong, userId=022b17724229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f0d211e555f, moduleTitle=Eur Urol Focus：非转移性前列腺癌根治术后尿失禁的患者和肿瘤相关预后因素分析 , moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1f0d211e555f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589477, encodeId=720415894e746, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, objectTitle=Prostate Cancer P D：非转移性前列腺癌中局部治疗与根治性前列腺切除术的比较：倾向性评分匹配研究, objectType=article, longId=206746, objectId=ac1a206e46c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac1a206e46c9, replyNumber=0, likeNumber=49, createdTime=2021-02-05, rootId=0, userName=jinweidong, userId=022b17724229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac1a206e46c9, moduleTitle=Prostate Cancer P D：非转移性前列腺癌中局部治疗与根治性前列腺切除术的比较：倾向性评分匹配研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ac1a206e46c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589476, encodeId=3cb615894e688, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, objectTitle=JAMA Oncology：一种新可以更好地预测非转移性前列腺癌患者预后的新分期系统, objectType=article, longId=202517, objectId=e79120251eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e79120251eaf, replyNumber=0, likeNumber=55, createdTime=2020-10-27, rootId=0, userName=jinweidong, userId=022b17724229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e79120251eaf, moduleTitle=JAMA Oncology：一种新可以更好地预测非转移性前列腺癌患者预后的新分期系统, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e79120251eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589475, encodeId=73ce15894e51d, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, objectTitle=NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！, objectType=article, longId=200507, objectId=259720050e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=259720050e88, replyNumber=0, likeNumber=59, createdTime=2020-09-12, rootId=0, userName=jinweidong, userId=022b17724229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=259720050e88, moduleTitle=NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=259720050e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589474, encodeId=007b15894e4d1, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, objectTitle=拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌, objectType=article, longId=191239, objectId=94ff191239b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94ff191239b4, replyNumber=0, likeNumber=62, createdTime=2020-04-03, rootId=0, userName=jinweidong, userId=022b17724229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94ff191239b4, moduleTitle=拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=94ff191239b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589473, encodeId=636015894e3c7, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, objectTitle=2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间, objectType=article, longId=183719, objectId=f1bc183e1902, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1bc183e1902, replyNumber=0, likeNumber=55, createdTime=2019-11-30, rootId=0, userName=jinweidong, userId=022b17724229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1bc183e1902, moduleTitle=2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f1bc183e1902)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589472, encodeId=393415894e224, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, objectTitle=FDA扩大了辉瑞/安斯泰来的Xtandi的适应症用以治疗非转移性前列腺癌, objectType=article, longId=144569, objectId=4e5f14456932, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e5f14456932, replyNumber=0, likeNumber=50, createdTime=2018-07-18, rootId=0, userName=jinweidong, userId=022b17724229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e5f14456932, moduleTitle=FDA扩大了辉瑞/安斯泰来的Xtandi的适应症用以治疗非转移性前列腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4e5f14456932)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589471, encodeId=107c15894e145, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, objectTitle=2017 IOF立场声明：非转移性前列腺癌患者脆性骨折的预防, objectType=article, longId=110304, objectId=e39a110304e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e39a110304e3, replyNumber=0, likeNumber=64, createdTime=2017-08-21, rootId=0, userName=jinweidong, userId=022b17724229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e39a110304e3, moduleTitle=2017 IOF立场声明：非转移性前列腺癌患者脆性骨折的预防, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e39a110304e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589470, encodeId=291015894e01c, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, objectTitle=JAMA Oncol：放射治疗对新诊断非转移性前列腺癌患者有益（STAMPEDE试验）, objectType=article, longId=59664, objectId=71ef5966413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71ef5966413, replyNumber=0, likeNumber=44, createdTime=2015-11-30, rootId=0, userName=jinweidong, userId=022b17724229, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71ef5966413, moduleTitle=JAMA Oncol：放射治疗对新诊断非转移性前列腺癌患者有益（STAMPEDE试验）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=71ef5966413)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

非转移性前列腺癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#前列腺切除术# #非转移性前列腺癌# #癌症特异性生存率#

Eur Urol Oncol：根治性前列腺切除术对根据STAMPEDE标准选择的高风险非转移性前列腺癌男性生存率的影响

2024-07-21发表于上海

jinweidong (审核中...)

前往app查看评论内容

#非转移性前列腺癌#

Eur Urol：非转移性前列腺癌患者中，高强度聚焦超声局部治疗后的癌症控制结果

2022-02-19

jinweidong (审核中...)

前往app查看评论内容

#非转移性前列腺癌#

Eur Urol Focus：非转移性前列腺癌根治术后尿失禁的患者和肿瘤相关预后因素分析

2021-05-26

jinweidong (审核中...)

前往app查看评论内容

#非转移性前列腺癌#

Prostate Cancer P D：非转移性前列腺癌中局部治疗与根治性前列腺切除术的比较：倾向性评分匹配研究

2021-02-05

jinweidong (审核中...)

前往app查看评论内容

#非转移性前列腺癌#

JAMA Oncology：一种新可以更好地预测非转移性前列腺癌患者预后的新分期系统

2020-10-27

jinweidong (审核中...)

前往app查看评论内容

#非转移性前列腺癌#

NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！

2020-09-12

jinweidong (审核中...)

前往app查看评论内容

#非转移性前列腺癌#

拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌

2020-04-03

jinweidong (审核中...)

前往app查看评论内容

#非转移性前列腺癌#

2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间

2019-11-30

jinweidong (审核中...)

前往app查看评论内容

#非转移性前列腺癌#

FDA扩大了辉瑞/安斯泰来的Xtandi的适应症用以治疗非转移性前列腺癌

2018-07-18

jinweidong (审核中...)

前往app查看评论内容

#非转移性前列腺癌#

2017 IOF立场声明：非转移性前列腺癌患者脆性骨折的预防

2017-08-21

jinweidong (审核中...)

前往app查看评论内容

#非转移性前列腺癌#

JAMA Oncol：放射治疗对新诊断非转移性前列腺癌患者有益（STAMPEDE试验）

2015-11-30

科室
- - 订阅+
  - 更多科室
工具
服务